2023
DOI: 10.1016/j.xcrm.2023.101289
|View full text |Cite
|
Sign up to set email alerts
|

An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2

Aliyah B. Silver,
Stephany Y. Tzeng,
Mallory Lager
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 79 publications
0
2
0
Order By: Relevance
“…To overcome these limitations, our lab developed intramolecularly assembled cytokine/antibody fusion proteins (immunocytokines, ICs) that fuse IL-2 to the N-terminus of the F10 and F5111 antibody light chains. These engineered ICs (denoted F10 IC and F5111 IC) selectively bias the effects of IL-2 and prolong cytokine half-life in serum, and they show encouraging preclinical promise as molecular therapeutics to treat cancer or autoimmune conditions (Leonard et al, 2023;Silver et al, 2023;VanDyke et al, 2022).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…To overcome these limitations, our lab developed intramolecularly assembled cytokine/antibody fusion proteins (immunocytokines, ICs) that fuse IL-2 to the N-terminus of the F10 and F5111 antibody light chains. These engineered ICs (denoted F10 IC and F5111 IC) selectively bias the effects of IL-2 and prolong cytokine half-life in serum, and they show encouraging preclinical promise as molecular therapeutics to treat cancer or autoimmune conditions (Leonard et al, 2023;Silver et al, 2023;VanDyke et al, 2022).…”
Section: Introductionmentioning
confidence: 99%
“…Subsequent studies have identified anti‐human IL‐2 analogs of both S4B6 and JES6‐1, denoted MAB602 (Krieg et al., 2010; Létourneau et al., 2010) and F5111 (Trotta et al., 2018), respectively. Subsequent protein engineering efforts developed the F10 antibody as a more immune effector cell‐biased iteration of MAB602 (Silver et al., 2023; VanDyke et al., 2022). Although the anti‐human IL‐2 antibodies F10 and F5111 were shown to therapeutically bias cytokine function (Krieg et al., 2010; Létourneau et al., 2010; Trotta et al., 2018), translation of non‐covalent cytokine/antibody complexes faces several challenges.…”
Section: Introductionmentioning
confidence: 99%